Posted by Michael Wonder on 08 May 2025
Patient group urges quick reimbursement of Besremi for polycythemia vera
7 May 2025 - The Korea Leukemia Patients Organization has called for the reimbursement of Besremi (ropeginterferon alfa-2b), the only treatment alternative for patients with polycythemia vera, ahead of the upcoming reimbursement review committee meeting on Thursday this week.
The patient group issued a statement last Friday, urging the government and pharmaceutical companies to expedite the reimbursement process for Besremi.
